Modulation of the biological activity of bacterial endotoxin by incorporation into liposomes.
In an attempt to define the mechanism by which endotoxin induces its biological activity, we studied the effect of the incorporation of lipopolysaccharide and lipid A into phospholipid vesicles (liposomes) on the stimulation of the macrophage cell-line RAW 264.7 and on the coagulation of Limulus amoebocyte lysate. The incorporation of Salmonella minnesota smooth-and rough (Re) lipopolysaccharide or primarily monophosphoryl lipid A into multilamellar and small unilamellar vesicles consisting of phosphatidylcholine, phosphatidylserine and cholesterol (molar ratio 4:1:4) reduced the interleukin 1 inducing potency of these substances about 1000-fold. When corrected for the actual uptake of radiolabeled free and liposome-incorporated lipopolysaccharide by the cells, this difference amounted to 100- to 1000-fold. In addition, liposome-associated Re-lipopolysaccharide was about 1000-fold less potent in stimulating the Fc-receptor mediated uptake of IgG-coated sheep erythrocytes by the cells. The ability of lipopolysaccharide and lipid A to coagulate the Limulus amoebocyte lysate appeared to be at least 100-fold decreased upon incorporation into phospholipid vesicles. Control experiments demonstrated that liposomes prepared without lipopolysaccharide did not reduce the studied activities of free lipopolysaccharide. In conclusion, the incorporation of lipopolysaccharide into the liposomal membrane probably prevents the interaction of the hydrophobic portion of the lipid A component of lipopolysaccharide with the plasma-membrane structures involved in the activation of macrophages and with the proteins of the Limulus amoebocyte lysate. This indicates that the direct interaction of the lipid A moiety of lipopolysaccharide with the macrophage plasma-membrane is required to optimally trigger the studied responses.
D000818:Animals; D002460:Cell Line; D002462:Cell Membrane / Q000187:drug effects; D002784:Cholesterol; D006017:Glycolipids / Q000008:administration & dosage / Q000494:pharmacology; D007375:Interleukin-1 / Q000378:metabolism; D008033:Limulus Test; D008050:Lipid A / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000494:pharmacology*; D008081:Liposomes; D008262:Macrophage Activation / Q000187:drug effects*; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D010587:Phagocytosis / Q000187:drug effects; D010713:Phosphatidylcholines; D010718:Phosphatidylserines; D012475:Salmonella / Q000276:immunology
D006017:Glycolipids; D007375:Interleukin-1; D008050:Lipid A; D008070:Lipopolysaccharides; D008081:Liposomes; D010713:Phosphatidylcholines; D010718:Phosphatidylserines; C044283:lipid X; D002784:Cholesterol; C048436:monophosphoryl lipid A